These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 8811495)

  • 21. [High-dose chemoradiotherapy combined with recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) followed by autologous peripheral blood stem cell transplantation (PBSCT) in a case of refractory acute myelogenous leukemia (AML)].
    Tanosaki R; Okamoto S; Takahashi S; Inoue T; Kikuno K; Aoki Y; Takada M; Irie S; Shimane M; Tojo A
    Rinsho Ketsueki; 1993 Aug; 34(8):946-51. PubMed ID: 8105115
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of recombinant human granulocyte-macrophage colony-stimulating factor for chemotherapy-induced leukopenia in patients with non-small-cell lung cancer.
    Eguchi K; Kabe J; Kudo S; Mano K; Morinari H; Nakada K; Noda K; Saito Y; Tanaka T; Uzawa T
    Cancer Chemother Pharmacol; 1994; 34(1):37-43. PubMed ID: 8174201
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Granulocyte-macrophage colony-stimulating factor or granulocyte colony-stimulating factor infusion makes high-dose etoposide a safe outpatient regimen that is effective in lymphoma and myeloma patients.
    Gianni AM; Bregni M; Siena S; Magni M; Di Nicola M; Lombardi F; Tarella C; Pileri A; Bonadonna G
    J Clin Oncol; 1992 Dec; 10(12):1955-62. PubMed ID: 1280674
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Alterations in phenotype and cell-surface antigen expression levels of human monocytes: differential response to in vivo administration of rhM-CSF or rhGM-CSF.
    Schmid I; Baldwin GC; Jacobs EL; Isacescu V; Neagos N; Giorgi JV; Glaspy JA
    Cytometry; 1995 Jun; 22(2):103-10. PubMed ID: 7587740
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunization with recombinant human granulocyte-macrophage colony-stimulating factor as a vaccine adjuvant elicits both a cellular and humoral response to recombinant human granulocyte-macrophage colony-stimulating factor.
    McNeel DG; Schiffman K; Disis ML
    Blood; 1999 Apr; 93(8):2653-9. PubMed ID: 10194445
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase II study of recombinant human granulocyte-macrophage colony-stimulating factor in myelodysplastic syndrome and aplastic anemia.
    Takahashi M; Yoshida Y; Kaku K; Masaoka T; Moriyama Y; Nakanishi S; Kaneko T; Shibata A; Miwa S
    Acta Haematol; 1993; 89(4):189-94. PubMed ID: 8212999
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of intravenous versus subcutaneous recombinant human granulocyte-macrophage colony-stimulating factor in patients with primary myelodysplasia.
    Rosenfeld CS; Sulecki M; Evans C; Shadduck RK
    Exp Hematol; 1991 May; 19(4):273-7. PubMed ID: 2055292
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Eosinophilia resulting from administration of recombinant granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in a patient with T-gamma lymphoproliferative disease.
    Gonzales-Chambers R; Rosenfeld C; Winkelstein A; Dameshek L
    Am J Hematol; 1991 Feb; 36(2):157-9. PubMed ID: 2012068
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Low-dose monoclonal antibody CC49 administered sequentially with granulocyte-macrophage colony-stimulating factor in patients with metastatic colorectal cancer.
    Rucker R; Bresler HS; Heffelfinger M; Kim JA; Martin EW; Triozzi PL
    J Immunother; 1999 Jan; 22(1):80-4. PubMed ID: 9924703
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of neutrophil and monocyte function by microbicidal cell-kill assay in patients with cancer receiving granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor, or no cytokine after cytotoxic chemotherapy: a phase II trial.
    Nemunaitis J; Cox J; Meyer W; Courtney A; Hanson T; Green-Weaver C; Agosti J
    Am J Clin Oncol; 1998 Jun; 21(3):308-12. PubMed ID: 9626806
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of recombinant human granulocyte-macrophage colony-stimulating factor on platelet survival and activation using a nonhuman primate model.
    Tomer A; Stahl CP; McClure HM; Anderson DC; Myers LA; Liehl E; Winton EF
    Exp Hematol; 1993 Nov; 21(12):1577-82. PubMed ID: 8405239
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) subsequent to chemotherapy improves collection of blood stem cells for autografting in patients not eligible for bone marrow harvest.
    Haas R; Hohaus S; Egerer G; Ehrhardt R; Witt B; Hunstein W
    Bone Marrow Transplant; 1992 Jun; 9(6):459-65. PubMed ID: 1352717
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression.
    Antman KS; Griffin JD; Elias A; Socinski MA; Ryan L; Cannistra SA; Oette D; Whitley M; Frei E; Schnipper LE
    N Engl J Med; 1988 Sep; 319(10):593-8. PubMed ID: 3045544
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics of recombinant human granulocyte-macrophage colony-stimulating factor in children after intravenous and subcutaneous administration.
    Stute N; Furman WL; Schell M; Evans WE
    J Pharm Sci; 1995 Jul; 84(7):824-8. PubMed ID: 7562431
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase II trial of recombinant human granulocyte-macrophage colony-stimulating factor in patients undergoing allogeneic bone marrow transplantation from unrelated donors.
    Nemunaitis J; Anasetti C; Storb R; Bianco JA; Buckner CD; Onetto N; Martin P; Sanders J; Sullivan K; Mori M
    Blood; 1992 May; 79(10):2572-7. PubMed ID: 1586709
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) after chemotherapy in patients with non-Hodgkin's lymphoma; a placebo-controlled double blind phase III trial.
    Kaku K; Takahashi M; Moriyama Y; Nakahata T; Masaoka T; Yoshida Y; Shibata A; Kaneko T; Miwa S
    Leuk Lymphoma; 1993 Oct; 11(3-4):229-38. PubMed ID: 8260897
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combination therapy with interleukin-2 and antitumor monoclonal antibodies.
    Sondel PM; Hank JA
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S121-7. PubMed ID: 9457407
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of a chimeric anti-ganglioside GD2 antibody on cell-mediated lysis of human neuroblastoma cells.
    Barker E; Mueller BM; Handgretinger R; Herter M; Yu AL; Reisfeld RA
    Cancer Res; 1991 Jan; 51(1):144-9. PubMed ID: 1988079
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recombinant human granulocyte-macrophage colony-stimulating factor after combined chemotherapy in high-grade non-Hodgkin's lymphoma--a randomised pilot study.
    Bergmann L; Karakas T; Knuth A; Lautenschläger G; Mitrou PS; Hoelzer D
    Eur J Cancer; 1995 Dec; 31A(13-14):2164-8. PubMed ID: 8652236
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical and immunological effects of granulocyte-macrophage colony-stimulating factor coadministered with interleukin 2: a phase IB study.
    Schiller JH; Hank JA; Khorsand M; Storer B; Borchert A; Huseby-Moore K; Burns D; Wesly O; Albertini MR; Wilding G; Sondel PM
    Clin Cancer Res; 1996 Feb; 2(2):319-30. PubMed ID: 9816175
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.